RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis.

Authors

Kei Muro

Kei Muro

Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan

Kei Muro , Gyorgy Bodoky , Alvydas Cesas , Yee Chao , Philip Clingan , Shuichi Hironaka , Yoshito Komatsu , Galina Petrova Kurteva , Oleg N. Lipatov , Tomohiro Nishina , Sang Cheul Oh , Atsushi Ohtsu , Yasuhiro Shimada , Naotoshi Sugimoto , Eric Van Cutsem , Roberto Carlesi , Kumari Chandrawansa , Hansjochen Wilke

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Prevention, Diagnosis, and Screening

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 11)

DOI

10.1200/jco.2015.33.3_suppl.11

Abstract #

11

Poster Bd #

A11

Abstract Disclosures